Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 12:35PM GMT
Release Date Price: €60.28 (-0.23%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Good morning, everyone. I'm Brian Abrahams, senior biotech analyst at RBC Capital Markets. Our next presenting company is Sage, featuring their CEO, Barry Greene. Barry, thanks so much for joining us.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Brian, thanks for having us, and I'd like to thank RBC for organizing this today.

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Our pleasure.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

So maybe let's kick things off on the most imminent data catalysts coming up, the WATERFALL data for zuranolone in major depressive disorder. Can you maybe start by talking about your latest views on how some of the adjustments and changes that you made in things like dosing, inclusion criteria and conduct

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot